hypotension. Hypotension, unspecified
Conditions
Interventions
Intervention 1: Intervention group: receive sertraline 50 mg daily (manufactured by Hayan Darou Company) in during first week and it is increased to 100 mg daily and patients are received sertraline 1
Treatment - Drugs
Placebo
Intervention group: receive sertraline 50 mg daily (manufactured by Hayan Darou Company) in during first week and it is increased to 100 mg daily and patients are received sertraline 100 mg daily for
Control group: receive one placebo tablet daily (totally like sertraline but without therapeutic properties) for 4 weeks.
Sponsors
Semnan University of Medical Sciences, Deputy of Research and Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Permanent hemodialysis patients for the at least 3 months that in at least 50 percent of their hemodialysis cases in last 3 months, having intra-dialytic hypotension; perform at least 4 hours hemodialysis for 3 times per week; concentration of dialysis fluid: Na: 106 mEq/L, Ca: 5.2 mEq/L, K: 2 mEq/L and mg: 1 mEq/L, Cl: 111.5 mEq/L, HCO3 3.35; fluid dialysis flow: 500 to 600 ml/min; blood flow: 250 to 300 ml/min; antihypertensive agents received during dialysis; available for at least 8 weeks (study time). Exclusion criteria: Performing hemodialysis in different treatment centers during the time of the study; having mental illness that use the SSRIs drug.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum creatinine level. Timepoint: Before, 12, 24 and 48 hours after intervention. Method of measurement: Exam.;Blood Urea Nitrogen (BUN). Timepoint: Before, 12, 24 and 48 hours after intervention. Method of measurement: Exam. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaliheh Yarmohammadi
Semnan University of Medical Sciences
Outcome results
None listed